HighTide Therapeutics, Inc. (2511.HK) presented new findings on the renoprotective effects of its lead candidate HTD1801 in an oral presentation at the 63rd European Renal Association (ERA) Congress in Glasgow, UK. The data, presented on June 4, 2026, provide mechanistic insights into how HTD1801 may protect kidney function, building on positive results from Phase III trials.
HTD1801 is a first-in-class anti-inflammatory metabolic modulator (AIMM) that targets the AMPK-NLRP3 axis. In the completed Phase III trials (SYMPHONY-1 and 2), the drug demonstrated significant improvement in renal function in patients with Type 2 Diabetes Mellitus (T2DM) and baseline eGFR of 60–90 mL/min/1.73m². Treatment with HTD1801 resulted in a mean increase of +3.08 mL/min/1.73m² in eGFR after 52 weeks (95% CI: 0.46–5.70), without evidence of hyperfiltration or fluid retention. These clinical observations suggested that HTD1801 may differentiate from existing therapies, with the potential to delay or prevent disease progression.
The new study, conducted in collaboration with the research team led by Academician Jiandong Jiang at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, explored the mechanistic basis underlying these clinical observations. In glucose- and palmitic acid-induced podocyte injury models, HTD1801 significantly preserved podocyte viability and inhibited apoptosis. The compound also restored expression of the key podocyte structural proteins nephrin and podocin, while reducing levels of the inflammatory marker phosphorylated NF-kB and the apoptosis executioner caspase-3.
In a diabetic nephropathy (DN) model, HTD1801 demonstrated dose-dependent improvements in renal architecture, reduced tubular injury scores, attenuated renal inflammatory and fibrotic changes, and drove a robust decrease in 24-hour urinary microalbumin. The study systematically demonstrated that HTD1801 suppresses podocyte inflammation and apoptosis while stabilizing glomerular structure, providing the latest findings supporting its renoprotective potential.
Dr Filip Surmont, Chief Medical Officer of HighTide Therapeutics, stated, "This study provides the first evidence into the renoprotective effects of HTD1801 at the podocyte and glomerular levels. The convergence of clinical and preclinical data further supports the disease-modifying potential of HTD1801 and its ability to target fundamental pathophysiologic processes in CKD or other renal diseases." He added that the company will continue advancing the clinical development of HTD1801 across CKD and related indications.
HTD1801 is an orally delivered, anti-inflammatory metabolic modulator that, as a single molecule, exerts a unique dual mechanism of action through activation of AMP Kinase and inhibition of the NLRP3 inflammasome. Multiple global clinical studies have demonstrated comprehensive benefits, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. These findings support the potential of HTD1801 to serve as a foundational therapy in cardiovascular–kidney–metabolic (CKM) disease management.
For more information about HighTide Therapeutics and HTD1801, visit www.hightidetx.com.
